68GaNOTA-Anti-MMR-VHH2

N/A

Report date: 2025/11/26 17:11:14

Base Information

Drug Name68GaNOTA-Anti-MMR-VHH2

Drug Alias NameN/A

ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionPositron-emission tomography enhancersRadionuclide imaging enhancersMacrophage mannose receptor 1 binders

TargetsMacrophage mannose receptor 1

Therapy Area/IndicationsSarcoidosisLymphohistiocytosis, HemophagocyticAtherosclerosis +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversitair Ziekenhuis Brussel

China Registration ClassN/A

Develop Information

Active CompaniesUniversitair Ziekenhuis Brussel

Inactive CompaniesN/A

Active IndicationsSarcoidosisLymphohistiocytosis, HemophagocyticAtherosclerosis +[7]

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A